Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications?

All topical ophthalmic agents should be considered potentially potent systemically.

[1]  C. Ng,et al.  A case of melancholic depression induced by β‐blocker antiglaucoma agents , 2008 .

[2]  W. Frishman,et al.  Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension , 2008, Cardiology in review.

[3]  I. Goldberg,et al.  Co‐prescribing of topical and systemic beta‐blockers in patients with glaucoma: a quality use of medicine issue in Australian practice , 2007, Clinical & experimental ophthalmology.

[4]  Z. Yıldırım,et al.  Preventive effect of lacrimal occlusion on topical timolol‐induced bronchoconstriction in asthmatics , 2004, Clinical & experimental ophthalmology.

[5]  D. Zadok,et al.  Systemic Side Effects of Ophthalmic Drops , 2004, Clinical pediatrics.

[6]  T. Kaila,et al.  Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  J. Lai,et al.  Topical chloramphenicol for eye infections. , 2002, Hong Kong medical journal = Xianggang yi xue za zhi.

[8]  D. Lam,et al.  A prospective study on ocular hypertensive and antiinflammatory response to different dosages of fluorometholone in children. , 2001, Ophthalmology.

[9]  B. C. Weston,et al.  Migraine headache associated with latanoprost. , 2001, Archives of ophthalmology.

[10]  D. Lam,et al.  A Prospective Study on Ocular Hypertensive and Antiinflammatory Response to Different Dosages of Fluorometholone in Children , 2001 .

[11]  J. Schuman.  Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol , 2000 .

[12]  P. R. Lewis,et al.  Topical therapies for glaucoma: what family physicians need to know. , 1999, American family physician.

[13]  T. Lancaster,et al.  Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database , 1998, BMJ.

[14]  M. B. Shields,et al.  Physicians' Guide to Interactions Between Glaucoma and Systemic Medications , 1997, Journal of glaucoma.

[15]  S. Wesselingh,et al.  It is time to stop using topical chloramphenicol. , 1997, Australian and New Zealand journal of ophthalmology.

[16]  P Diggory,et al.  Medical treatment of glaucoma--a reappraisal of the risks. , 1996, The British journal of ophthalmology.

[17]  E O'Donoghue,et al.  Beta blockers and the elderly with glaucoma: are we adding insult to injury? , 1995, The British journal of ophthalmology.

[18]  A. Urtti,et al.  Minimizing systemic absorption of topically administered ophthalmic drugs. , 1993, Survey of ophthalmology.

[19]  R. Glynn,et al.  Falls in elderly patients with glaucoma. , 1991, Archives of ophthalmology.